CR20140583A - Aminotriazolopirimidina para uso en tratamiento de inflamación y composiciones farmacéuticas de la misma - Google Patents

Aminotriazolopirimidina para uso en tratamiento de inflamación y composiciones farmacéuticas de la misma

Info

Publication number
CR20140583A
CR20140583A CR20140583A CR20140583A CR20140583A CR 20140583 A CR20140583 A CR 20140583A CR 20140583 A CR20140583 A CR 20140583A CR 20140583 A CR20140583 A CR 20140583A CR 20140583 A CR20140583 A CR 20140583A
Authority
CR
Costa Rica
Prior art keywords
treatment
aminotriazolopirimidine
inflammation
same
pharmaceutical compositions
Prior art date
Application number
CR20140583A
Other languages
English (en)
Inventor
T Klooster Gerben Albert Eleutherius Van
Reginald Christophe Xavier Brys
Rompaey Luc Juliaan Corina Van
Florence Sylvie Namour
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of CR20140583A publication Critical patent/CR20140583A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere al nuevo uso médico del compuesto de conformidad con la Fórmula I, en particular en el tratamiento de afecciones inflamatorias, enfermedades autoinmunitarias, enfermedades proliferativas, alergias, rechazo de trasplante, enfermedades que implican in deterioro de la producción de cartílago y/o enfermedades asociadas con la hipersecreción de IL6 o interferones.
CR20140583A 2012-06-22 2014-12-16 Aminotriazolopirimidina para uso en tratamiento de inflamación y composiciones farmacéuticas de la misma CR20140583A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261663520P 2012-06-22 2012-06-22
PCT/EP2013/061914 WO2013189771A1 (en) 2012-06-22 2013-06-10 Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
CR20140583A true CR20140583A (es) 2015-02-10

Family

ID=48577773

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140583A CR20140583A (es) 2012-06-22 2014-12-16 Aminotriazolopirimidina para uso en tratamiento de inflamación y composiciones farmacéuticas de la misma

Country Status (34)

Country Link
US (2) US9284311B2 (es)
EP (1) EP2863950B1 (es)
JP (2) JP6238975B2 (es)
KR (1) KR102078069B1 (es)
CN (2) CN104379173A (es)
AR (1) AR091395A1 (es)
AU (1) AU2013279597B2 (es)
BR (1) BR112014031626A8 (es)
CA (1) CA2875619C (es)
CL (1) CL2014003462A1 (es)
CO (1) CO7160085A2 (es)
CR (1) CR20140583A (es)
CY (1) CY1120643T1 (es)
DK (1) DK2863950T3 (es)
EA (1) EA029084B1 (es)
ES (1) ES2685985T3 (es)
HR (1) HRP20181364T8 (es)
HU (1) HUE038878T2 (es)
IL (1) IL235923B (es)
LT (1) LT2863950T (es)
MA (1) MA37775A1 (es)
MX (1) MX368511B (es)
MY (1) MY177334A (es)
NZ (1) NZ702480A (es)
PE (1) PE20150187A1 (es)
PH (1) PH12014502615B1 (es)
PL (1) PL2863950T3 (es)
PT (1) PT2863950T (es)
SG (2) SG11201408123SA (es)
SI (1) SI2863950T1 (es)
TW (1) TWI586352B (es)
UA (1) UA112804C2 (es)
UY (1) UY34855A (es)
WO (1) WO2013189771A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201402070D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Pharmaceutical compositions for the treatment of inflammatory disorders
RS64677B1 (sr) * 2015-04-13 2023-11-30 Galapagos Nv Metode lečenja kardiovaskularnih poremećaja
JP2018511620A (ja) 2015-04-13 2018-04-26 ガラパゴス・ナムローゼ・フェンノートシャップＧａｌａｐａｇｏｓ Ｎ．Ｖ． 炎症性障害の治療のための方法
AU2016257892A1 (en) * 2015-05-05 2017-11-09 Concert Pharmaceuticals, Inc. Deuterated filgotinib
CN105061420B (zh) * 2015-06-04 2017-09-05 南京旗昌医药科技有限公司 一种jak抑制剂的晶型及其制备方法和应用
US20170173034A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders
WO2017106568A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and a bromodomain inhibitor for treating cancer
WO2017106566A1 (en) 2015-12-17 2017-06-22 Gilead Sciences, Inc. Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
WO2017133423A1 (zh) * 2016-02-02 2017-08-10 深圳市塔吉瑞生物医药有限公司 一种取代的吡啶酰胺类化合物及其应用
WO2018087202A1 (en) 2016-11-10 2018-05-17 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases
GB201702603D0 (en) 2017-02-17 2017-04-05 Galápagos Nv Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
SMT202400019T1 (it) 2017-03-14 2024-03-13 Galapagos Nv Composizioni farmaceutiche comprendenti un inibitore jak
GB201808575D0 (en) * 2018-05-24 2018-07-11 Galapagos Nv Methods for the treatment of psoriatic arthrits
US12171764B2 (en) 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
CN113677676A (zh) * 2019-03-30 2021-11-19 联合化学实验室有限公司 一种制备非戈替尼及其中间体的新方法
JP7315166B2 (ja) * 2019-06-10 2023-07-26 富士通株式会社 グラフェンナノリボンネットワーク膜の製造方法及び電子装置の製造方法
CN111686106B (zh) * 2020-04-05 2022-07-15 温州医科大学附属第一医院 提高Dicer表达的化合物在制备药物中的应用
CN114409675B (zh) * 2022-01-07 2023-08-04 重庆医科大学 螺环异恶唑酮色满衍生物在制备用于治疗jak1介导的疾病药物中的用途
WO2026027676A1 (en) 2024-07-31 2026-02-05 Alfasigma S.P.A. Biomarkers for determining treatment of ulcerative colitis with filgotinib
WO2026027669A1 (en) 2024-07-31 2026-02-05 Alfasigma S.P.A. Biomarkers for determining treatment of ulcerative colitis with filgotinib

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2549862T3 (es) * 2006-08-30 2015-11-02 Cellzome Limited Derivados de triazol como inhibidores de quinasa
TWI453207B (zh) * 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
NZ597140A (en) * 2009-06-05 2014-01-31 Cephalon Inc Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
TWI462920B (zh) * 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JO3030B1 (ar) * 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات

Also Published As

Publication number Publication date
JP2015520198A (ja) 2015-07-16
MX2014014800A (es) 2015-02-12
PT2863950T (pt) 2018-10-10
EP2863950A1 (en) 2015-04-29
HUE038878T2 (hu) 2018-12-28
EA201590071A1 (ru) 2015-04-30
HRP20181364T1 (hr) 2018-10-19
US9284311B2 (en) 2016-03-15
LT2863950T (lt) 2018-09-25
JP6238975B2 (ja) 2017-11-29
IL235923B (en) 2018-11-29
UY34855A (es) 2014-01-31
CL2014003462A1 (es) 2015-02-27
ES2685985T3 (es) 2018-10-15
CN104379173A (zh) 2015-02-25
BR112014031626A8 (pt) 2021-10-19
SG10201700125VA (en) 2017-02-27
MA37775A1 (fr) 2017-04-28
EA029084B1 (ru) 2018-02-28
UA112804C2 (uk) 2016-10-25
PH12014502615A1 (en) 2015-01-21
CA2875619A1 (en) 2013-12-27
AU2013279597A1 (en) 2015-01-15
HK1208368A1 (en) 2016-03-04
CY1120643T1 (el) 2019-12-11
TW201400114A (zh) 2014-01-01
IL235923A0 (en) 2015-01-29
PL2863950T3 (pl) 2019-02-28
CA2875619C (en) 2020-11-24
HRP20181364T8 (hr) 2018-12-28
PH12014502615B1 (en) 2015-01-21
AU2013279597B2 (en) 2017-04-20
PE20150187A1 (es) 2015-02-27
AR091395A1 (es) 2015-02-04
CO7160085A2 (es) 2015-01-15
JP2018048185A (ja) 2018-03-29
WO2013189771A1 (en) 2013-12-27
US20160296529A1 (en) 2016-10-13
TWI586352B (zh) 2017-06-11
MX368511B (es) 2019-10-07
EP2863950B1 (en) 2018-07-18
SI2863950T1 (sl) 2018-10-30
US20130345209A1 (en) 2013-12-26
KR20150023048A (ko) 2015-03-04
MY177334A (en) 2020-09-12
DK2863950T3 (en) 2018-09-03
CN107998136A (zh) 2018-05-08
NZ702480A (en) 2016-11-25
SG11201408123SA (en) 2015-01-29
KR102078069B1 (ko) 2020-02-17
BR112014031626A2 (pt) 2017-06-27

Similar Documents

Publication Publication Date Title
CO7160085A2 (es) Aminotriazolopiridina para uso en tratamiento de inflamacion y composiciones farmaceuticas de la misma
TW201613601A (en) Pharmaceutical compositions for the treatment of inflammatory disorders
CL2017002650A1 (es) Compuestos novedosos
MX2020003368A (es) Sal de acido maleico de {5-[4-(1,1-dioxo-tiomorfolin-4-ilmetil)-fe nil]-[1,2,4]triazolo[1,5-a]piridin-2-il}-amida del acido ciclopropancarboxilico.
CL2016000153A1 (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
MX355653B (es) Compuesto novedoso util para el tratamiento de enfermedades degenerativas e inflamatorias.
CO6400172A2 (es) C5ar antagonistas
CL2018000413A1 (es) Composición y productos que comprenden células senescentes para su uso en la regeneración de tejidos
CR20110673A (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias
UY34616A (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
CL2015002030A1 (es) Dihidropirimidinomas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrofílica
CL2015003019A1 (es) Derivados biaromáticos antibacterianos
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
MX372772B (es) Enonas piridazolilo y pirimidinilo tricíclicas sustituidas con arilo y arilalquilo como moduladores de la inflamación antioxidantes.
BR112016016732A8 (pt) derivados de benzimidazol, seus usos, e composições farmacêuticas para tratamento de distúrbios inflamatórios
EA201892552A1 (ru) Фармацевтические композиции, содержащие антиоксиданты, направленные на митохондрии
IN2013MU02370A (es)
UY35004A (es) Forma amorfa estabilizada de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
CR20150641U (es) Composiciones farmacéuticas